Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1NET 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 5Lung Neoplasms 4Colorectal Neoplasms 4Prostatic Neoplasms 3Multiple Myeloma 2Lymphoma 2Gastrointestinal Neoplasms 2Support of the Family as a Caregiving System 1Stomach Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Otorhinolaryngologic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Mixed Dementias 1Meningeal Carcinomatosis 1Malignant Female Reproductive System Neoplasm 1Lymphoma, Follicular 1Localized Head and Neck Carcinoma 1Lewy Body Disease 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Disease 1Dementia, Vascular 1Dementia 1Cognitive Dysfunction 1Cigarette Smoking-Related Carcinoma 1Cardiovascular Diseases 1

Interventions

lutetium Lu 177 dotatate 21Magnetic Resonance Spectroscopy 10pembrolizumab 9Specimen Handling 7Everolimus 7cabozantinib 6Nivolumab 6lenvatinib 5Capecitabine 5177Lu-octreotide, DOTA(0)-Tyr(3)- 5surufatinib 4olaparib 4amino-acid, glucose, and electrolyte solution 4lanreotide 3atezolizumab 3Temozolomide 3Octreotide 3Lutetium-177 3Ipilimumab 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3gallium Ga 68 dotatate 2fludarabine phosphate 2fludarabine 2avelumab 2X-Rays 2Radiotherapy 2Phantoms, Imaging 2PM 01183 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Referral and Consultation × 1 year × Clear all
NCT06908629 2025-08-26

Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors

Barbara Ann Karmanos Cancer Institute

Phase NA Recruiting
120 enrolled
EndocrineGastrointestinalNETPlasma cell

Gastrointestinal Neoplasms, Multiple Myeloma, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡